Ibrutinib dosing patterns
| Dosing patterns . | Komodo n = 3342 . | Acentrus n = 1171 . |
|---|---|---|
| Patients with a DA observed anytime during 1L therapy, n (%) | 608 (18.2) | 229 (19.6) |
| Time to first DA, mo, mean ± SD | 9.9 ± 10.7 | 9.0 ± 9.2 |
| DA within 3-6 mo, n (%) | 141 (23.2) | 66 (28.8) |
| DA within 3-9 mo, n (%) | 218 (35.9) | 87 (38.0) |
| DA within 3-12 mo, n (%) | 281 (46.2) | 111 (48.5) |
| Dosing patterns following first DA, n (%) | ||
| Patients staying on reduced dose for the remainder of 1L treatment | 425 (69.9) | 138 (60.3) |
| Patients returning to initial starting dose (420 mg/d) | 69 (11.3) | 25 (10.9) |
| Patients further reducing their dose | 89 (14.6) | 22 (9.6) |
| Patients with other dosing patterns after first DA (varying dose over time) | 25 (4.1) | 44 (19.2) |
| Dosing patterns . | Komodo n = 3342 . | Acentrus n = 1171 . |
|---|---|---|
| Patients with a DA observed anytime during 1L therapy, n (%) | 608 (18.2) | 229 (19.6) |
| Time to first DA, mo, mean ± SD | 9.9 ± 10.7 | 9.0 ± 9.2 |
| DA within 3-6 mo, n (%) | 141 (23.2) | 66 (28.8) |
| DA within 3-9 mo, n (%) | 218 (35.9) | 87 (38.0) |
| DA within 3-12 mo, n (%) | 281 (46.2) | 111 (48.5) |
| Dosing patterns following first DA, n (%) | ||
| Patients staying on reduced dose for the remainder of 1L treatment | 425 (69.9) | 138 (60.3) |
| Patients returning to initial starting dose (420 mg/d) | 69 (11.3) | 25 (10.9) |
| Patients further reducing their dose | 89 (14.6) | 22 (9.6) |
| Patients with other dosing patterns after first DA (varying dose over time) | 25 (4.1) | 44 (19.2) |
SD, standard deviation.